股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 公司名稱: 智勤控股有限公司 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09913 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底法定/註冊股本總額： HKD 100,000,000 第 1 頁 共 10 頁 ...

Core Insights - The Chinese innovative pharmaceutical industry is undergoing a historic transformation, shifting from "fast followers" to "original creators" supported by solid data and market performance [1] - By 2025, the total value of innovative drug licensing transactions in China is expected to exceed $130 billion, with over 150 transactions, marking a historical high [1] - Shanghai's Pudong district is becoming a key hub for the global market, with significant achievements in CAR-T products and first-class new drugs [1] Industry Overview - China's pharmaceutical industry ranks second globally, with approximately 30% of innovative drugs in development worldwide [1] - The industry is entering a critical phase characterized by "innovation realization + global layout" [1] Company Developments - Chinese innovative drug companies are leveraging speed and cost-effectiveness to gain a competitive edge in the global market [3] - Companies like Maiwei Biotech and Jinsai Pharmaceutical are forming significant overseas business development (BD) partnerships, enhancing China's global competitiveness [3][4] - Maiwei Biotech has accelerated its BD efforts, securing exclusive licensing agreements for innovative therapies, including a $1 billion potential deal with Aditum Bio [4][5] Market Trends - By 2025, Pudong is expected to have approved four CAR-T products, accounting for 30% of the global total, and seven first-class new drugs, representing 14% of the national total [1] - The commercial sales of innovative drugs in Pudong are projected to exceed 11.6 billion yuan in 2024, with several new drugs achieving over 1 billion yuan in annual sales [10] Strategic Initiatives - Companies are focusing on building comprehensive global capabilities covering research, registration, and sales to transition from "licensing out" to "commercialization abroad" [10] - Jinsai Pharmaceutical has established local teams in the U.S. and Europe to manage clinical trials and seek collaboration opportunities [8] Innovation and Collaboration - The future of innovative drugs lies in international markets, with companies emphasizing deep understanding of disease biology as a core competitive advantage [5] - Companies are forming cooperative committees with BD partners to ensure project progress through information sharing and resource collaboration [5] Ecosystem Support - The rise of China's innovative drug industry is attributed to years of policy guidance, technological accumulation, and capital cultivation [23] - The unique industrial atmosphere, talent pool, and complete industrial chain in Zhangjiang are seen as core advantages for local companies [23][24] - Pudong's talent policies and supportive platforms are facilitating the rapid gathering of global talent resources [23] Future Outlook - The next 3-5 years are expected to see continued emphasis on internationalization and globalization among Chinese biopharmaceutical companies [14] - Companies are increasingly focusing on source innovation and high-quality BD potential to meet global market demands and achieve high valuations [17]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 智勤控股有限公司 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09913 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底法定/註 ...

CHI KAN HOLDINGS LIMITED (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號：9913) NOTIFICATION LETTER 通知信函 24 December 2025 Dear Non-Registered Holder(Note 1), Chi Kan Holdings Limited (the "Company") - Notice of publication of Chi Kan Holdings Limited - 2025 Interim Report ("Current Corporate Communication") on the Company's website The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at www.chik ...

CHI KAN HOLDINGS LIMITED 智勤控股有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號：9913) NOTIFICATION LETTER 通知信函 24 December 2025 Dear Registered Shareholder, Chi Kan Holdings Limited (the "Company") – Notice of publication of Chi Kan Holdings Limited - 2025 Interim Report ("Current Corporate Communication") on the Company's website By order of the Board Chi Kan Holdings Limited Lo Hon Kwong Chairman and Executive Director Notes: 各位登記股東： 智 勤 控 股 有 限 公 司（「本 公 司」） ...

CHI KAN HOLDINGS LIMITED 智勤控股有限公司 (Incorporated in the Cayman Islands with limited liability) Stock Code 股份代號：9913 (於開曼群島註冊成立的有限公司) CONTENTS 目錄 Page 頁次 Corporate Information 2 公司資料 Management Discussion and Analysis 4 管理層討論及分析 Corporate Governance and Other Information 10 企業管治及其他資料 Condensed Consolidated Statement of Comprehensive Income 19 簡明合併全面收益表 Condensed Consolidated Statement of Financial Position 21 簡明合併財務狀況表 Condensed Consolidated Statement of Changes in Equity 23 簡明合併權益變動表 Condensed Consolidated S ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 智勤控股有限公司 呈交日期: 2025年12月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09913 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底法定/註冊股本總額： HKD 100,000, ...

Group 1 - The company reported interim results for the six months ending September 30, 2025, with revenue of approximately HKD 372 million, representing a year-on-year decrease of 57.12% [1] - The company experienced a loss attributable to shareholders of approximately HKD 14.725 million, marking a shift from profit to loss compared to the previous year [1] - The loss per share was reported at HKD 0.0147 [1]

Core Viewpoint - Zhichun Holdings (09913) reported a significant decline in revenue and a shift to loss for the six months ending September 30, 2025, indicating potential challenges in its operational performance [1] Financial Performance - Revenue for the period was approximately HKD 372 million, representing a year-on-year decrease of 57.12% [1] - The company recorded a loss attributable to shareholders of approximately HKD 14.725 million, marking a transition from profit to loss compared to the previous year [1] - Earnings per share were reported at a loss of 1.47 HKD cents [1]

Core Viewpoint - The company reported a significant decline in revenue and a shift from profit to loss in its interim results for the six months ending September 30, 2025, primarily due to decreased earnings from its construction business [1] Financial Performance - The group's unaudited consolidated revenue was approximately HKD 372 million, down from approximately HKD 867 million in the same period of 2024 [1] - The loss attributable to the company's owners for the period was approximately HKD 14.7 million, compared to a profit of approximately HKD 17.5 million in the previous year [1] Business Segment Analysis - Revenue from the construction business was approximately HKD 64.2 million, a significant decrease from approximately HKD 590 million in the same period of 2024 [1] Management Commentary - The board acknowledged the transition from profit to loss but stated that the overall performance of the group remained relatively stable when considering the overall operating environment and business portfolio [1]